AB-Biotics acquires a patent for predicting antipsychotic-induced extrapyramidal symptoms

The Catalan biotech company AB-Biotics has acquired the rights to a patent of a technology developed by Universitat de Barcelona (UB), IDIBAPS, Hospital Clínic de Barcelona and CIBERSAM (Consorcio Centro de Investigación Biomédica en Red de Salud Mental). The patented method allows to predict the high or low risk of a patient treated with antipsychotic drugs developing extrapyramidal symptoms. The patent inventors are Amalia Lafuente Flo, Sergi Mas Herrero and Cristina Magdalena Grau from UB; Patricia Gassò Astorga from IDIBAPS and UB; and, Miguel Bernardo Arroyo from Hospital Clínic, UB and CIBERSAM. The project has been managed from the Fundació Clínic Innovation Department.

Extrapyramidal symptoms are side effects induced by antipsychotic drugs affect patient movement and include muscle rigidity, parkinsonism, akinesia (inability to initiate movement) and akathisia (inability to remain motionless), among others. This information provided by the new method helps doctors identify the most appropriate treatment for each patient, since the side effects are a major cause of abandonment of such treatments.

This technology will be incorporated into Neurofarmagen, a genetic test developed by AB-Biotics which identifies most optimum medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva. Neurofarmagen is currently marketed in Spain, through Almirall; in Brazil, through GlaxoSmithKline, and Mexico, through Scienta Farma.

More information in www.ab-biotics.com